research Clinical Evaluation of the MIRA Technique in Cellulite Treatment: A Retrospective Case–Control Study
The MIRA technique improves cellulite treatment results and patient satisfaction.
Search
for
Sort by
Research
990-1000 / 1000+ results research Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series
Intralesional triamcinolone effectively reduces pain and inflammation in hidradenitis suppurativa flares.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Effect of body mass index (BMI) on phenotypic features of polycystic ovary syndrome (PCOS) in Singapore women: a prospective cross-sectional study
High BMI worsens hair growth in women with PCOS.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Hair mass index obtained by cross-section trichometry: an objective and clinically useful parameter to quantify hair in chemotherapy-induced alopecia
Hair mass index is a precise way to measure hair loss in chemotherapy patients.
research European expert consensus statement on the systemic treatment of alopecia areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Appraisal of guidelines for androgenetic alopecia using the Appraisal of Guidelines for Research and Evaluation II instrument
European guideline best for treating hair loss; involve stakeholders and patients for improvement.
research Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.